Study Details
Full Title
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS PRASINEZUMAB IN PARTICIPANTS WITH EARLY-STAGE PARKINSON’S DISEASE
Principal Investigator
Kathryn
Moore
Protocol Number
PRO00118941
NCT ID
NCT07174310
Phase
III
Enrollment Status
Open to Enrollment